At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 199 enrolled
Drug / intervention
Ozanimod +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating Ozanimod and Placebo for Ulcerative Colitis. Completed, enrolled 199 participants across 88 sites in 15 countries.
Detailed Summary
The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesAustralia, Belgium, Bulgaria, Canada, Greece, Hungary, Israel, Netherlands, New Zealand, Poland, Russia, Slovakia, South Korea, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartDec 2012
Primary CompletionMar 2015
Study CompletionAug 2019
TodayJul 2026
First PostedJul 23, 2012
Enrollment StartDec 26, 2012
Primary CompletionMar 10, 2015
Study CompletionAug 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 13.9 years ago
Interventions
Ozanimoddrug
Ozanimod capsules by mouth daily.
Placebodrug